|
1
|
Efficacy of lenalidomide in myelodysplastic syndromes.
|
N Engl J Med
|
2005
|
8.80
|
|
2
|
Phase II study of alisertib, a selective Aurora A kinase inhibitor, in relapsed and refractory aggressive B- and T-cell non-Hodgkin lymphomas.
|
J Clin Oncol
|
2013
|
2.46
|
|
3
|
Actin microfilament aggregation induced by withaferin A is mediated by annexin II.
|
Nat Chem Biol
|
2005
|
1.55
|
|
4
|
Aurora inhibitor MLN8237 in combination with docetaxel enhances apoptosis and anti-tumor activity in mantle cell lymphoma.
|
Biochem Pharmacol
|
2011
|
1.47
|
|
5
|
Thioredoxin-1 binds to the C2 domain of PTEN inhibiting PTEN's lipid phosphatase activity and membrane binding: a mechanism for the functional loss of PTEN's tumor suppressor activity.
|
Arch Biochem Biophys
|
2004
|
1.44
|
|
6
|
Update on Aurora Kinase Targeted Therapeutics in Oncology.
|
Expert Opin Drug Discov
|
2011
|
1.19
|
|
7
|
In vivo molecular pharmacology and antitumor activity of the targeted Akt inhibitor PX-316.
|
Oncol Res
|
2004
|
1.14
|
|
8
|
The c-Met receptor tyrosine kinase inhibitor MP470 radiosensitizes glioblastoma cells.
|
Radiat Oncol
|
2009
|
1.14
|
|
9
|
Specific inhibition of the Akt1 pleckstrin homology domain by D-3-deoxy-phosphatidyl-myo-inositol analogues.
|
Mol Cancer Ther
|
2003
|
1.14
|
|
10
|
A conserved glutamate residue in transmembrane helix 10 influences substrate specificity of rabbit OCT2 (SLC22A2).
|
J Biol Chem
|
2005
|
1.13
|
|
11
|
Final results of a multicenter phase 1 study of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia.
|
Leuk Lymphoma
|
2011
|
1.03
|
|
12
|
Alisertib (MLN8237) an investigational agent suppresses Aurora A and B activity, inhibits proliferation, promotes endo-reduplication and induces apoptosis in T-NHL cell lines supporting its importance in PTCL treatment.
|
Leuk Res
|
2012
|
0.97
|
|
13
|
MP470, a novel receptor tyrosine kinase inhibitor, in combination with Erlotinib inhibits the HER family/PI3K/Akt pathway and tumor growth in prostate cancer.
|
BMC Cancer
|
2009
|
0.96
|
|
14
|
A phase 2 randomized multicenter study of 2 extended dosing schedules of oral ezatiostat in low to intermediate-1 risk myelodysplastic syndrome.
|
Cancer
|
2011
|
0.95
|
|
15
|
An orally active small molecule TGF-beta receptor I antagonist inhibits the growth of metastatic murine breast cancer.
|
Anticancer Res
|
2009
|
0.92
|
|
16
|
AT7519, a cyclin-dependent kinase inhibitor, exerts its effects by transcriptional inhibition in leukemia cell lines and patient samples.
|
Mol Cancer Ther
|
2010
|
0.91
|
|
17
|
Mapping of the active site of glutamate carboxypeptidase II by site-directed mutagenesis.
|
FEBS J
|
2007
|
0.89
|
|
18
|
Amino acid changes in Drosophila alphaPS2betaPS integrins that affect ligand affinity.
|
J Biol Chem
|
2005
|
0.88
|
|
19
|
Identification of a lead small-molecule inhibitor of the Aurora kinases using a structure-assisted, fragment-based approach.
|
Mol Cancer Ther
|
2006
|
0.84
|
|
20
|
Targeting aurora2 kinase in oncogenesis: a structural bioinformatics approach to target validation and rational drug design.
|
Mol Cancer Ther
|
2003
|
0.84
|
|
21
|
Design and activity of a murine and humanized anti-CEACAM6 single-chain variable fragment in the treatment of pancreatic cancer.
|
Cancer Res
|
2009
|
0.83
|
|
22
|
AT9283, a novel aurora kinase inhibitor, suppresses tumor growth in aggressive B-cell lymphomas.
|
Int J Cancer
|
2011
|
0.82
|
|
23
|
Monoclonal antibody therapies targeting pancreatic ductal adenocarcinoma.
|
Curr Drug Discov Technol
|
2006
|
0.80
|
|
24
|
An integrin-targeted, pan-isoform, phosphoinositide-3 kinase inhibitor, SF1126, has activity against multiple myeloma in vivo.
|
Cancer Chemother Pharmacol
|
2013
|
0.80
|
|
25
|
Monoclonal antibodies as therapeutics in human malignancies.
|
Future Oncol
|
2014
|
0.80
|
|
26
|
Novel targeted therapies and combinations for the treatment of multiple myeloma.
|
Cardiovasc Hematol Disord Drug Targets
|
2013
|
0.79
|
|
27
|
Novel mutations in a patient with ALK-rearranged lung cancer.
|
N Engl J Med
|
2014
|
0.78
|
|
28
|
Modulation of ligand binding by alternative splicing of the alphaPS2 integrin subunit.
|
J Cell Biochem
|
2007
|
0.78
|
|
29
|
Variation in cytotoxic T-lymphocyte responses to peptides derived from tyrosinase-related protein-2.
|
Hum Immunol
|
2007
|
0.77
|
|
30
|
CTL recognition of a novel HLA-A*0201-binding peptide derived from glioblastoma multiforme tumor cells.
|
Cancer Immunol Immunother
|
2011
|
0.77
|
|
31
|
Will MDR-1/P-gp modulators provide clinical benefit in hematologic malignancies?
|
Leuk Res
|
2006
|
0.76
|
|
32
|
Translational advances and novel therapies for pancreatic ductal adenocarcinoma: hope or hype?
|
Expert Rev Mol Med
|
2009
|
0.76
|
|
33
|
Laparoscopic hyperthermic intraperitoneal chemotherapy (HIPEC) for palliative treatment of malignant ascites from gastrointestinal stromal tumours.
|
J Palliat Care
|
2012
|
0.75
|
|
34
|
An analog of withaferin A activates the MAPK and glutathione "stress" pathways and inhibits pancreatic cancer cell proliferation.
|
Cancer Invest
|
2011
|
0.75
|